Feasibility and Advantage of Adding 131i-Mibg to 90y-Dotatoc for Treatment of Patients With Advanced Stage Neuroendocrine Tumors

EJNMMI Research - Germany
doi 10.1186/s13550-014-0038-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Semi-Automatic 3d-Volumetry of Liver Metastases From Neuroendocrine Tumors to Improve Combination Therapy With 177Lu-Dotatoc and 90y-Dotatoc

Diagnostic and Interventional Radiology
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2016English

Current Treatment Strategies for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Clinical Diabetes and Endocrinology
EndocrinologyMetabolismDiabetes
2018English

Effects and Safety of 131i-Metaiodobenzylguanidine (MIBG) Radiotherapy in Malignant Neuroendocrine Tumors: Results From a Multicenter Observational Registry

Endocrine Journal
EndocrinologyMetabolismDiabetes
2014English

Intraarterial Treatment of GEP NET: 68Ga-Dotatoc SUV Cannot Predict 90y-Dotatoc Uptake

Clinical Cancer Research
Cancer ResearchOncology
2011English

Comparative Biodistribution and Radiation Dosimetry of 68Ga-Dotatoc and 68Ga-Dotatate in Patients With Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Treatment for Advanced Tumors: SRC Reclaims Center Stage

Clinical Cancer Research
Cancer ResearchOncology
2006English

68 Ga-Dotatoc Imaging of Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Toxicity of Upfront 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy in Newly Diagnosed Neuroblastoma Patients: A Retrospective Analysis

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2013English

Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors

Oncologist
Cancer ResearchMedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy